AR104882A1 - DERIVADOS DE 2-(1-HETEROARILPIPERAZIN-4-IL)METIL-1,4-BENZODIOXANO COMO ANTAGONISTAS DE a2C - Google Patents

DERIVADOS DE 2-(1-HETEROARILPIPERAZIN-4-IL)METIL-1,4-BENZODIOXANO COMO ANTAGONISTAS DE a2C

Info

Publication number
AR104882A1
AR104882A1 ARP160101636A ARP160101636A AR104882A1 AR 104882 A1 AR104882 A1 AR 104882A1 AR P160101636 A ARP160101636 A AR P160101636A AR P160101636 A ARP160101636 A AR P160101636A AR 104882 A1 AR104882 A1 AR 104882A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
heterocyclic ring
substituted
heterocyclyl
Prior art date
Application number
ARP160101636A
Other languages
English (en)
Inventor
Haikarainen Anssi
Pohjakallio Antti
Pystynen Jarmo
Kumpulainen Esa
Wang Shouming
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of AR104882A1 publication Critical patent/AR104882A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud para compuestos con actividad antagonista de a2C y por lo tanto son útiles como antagonistas de a2C en el tratamiento de enfermedades del SNC. Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1), donde A es un anillo heterocíclico insaturado de cinco miembros que contiene 1, 2 ó 3 heteroátomo/s en el anillo cada uno seleccionado en forma independiente entre N, O y S, donde dicho anillo heterocíclico no está sustituido, o dicho anillo heterocíclico está sustituido con 1 sustituyente R¹, o dicho anillo heterocíclico está sustituido con 2 sustituyentes R¹ y R², o dicho anillo heterocíclico está sustituido con 3 sustituyentes R¹, R², y R³, o dicho anillo heterocíclico está sustituido con 4 sustituyentes R¹, R², R³, y R⁴; R¹ es C₁₋₆ alquilo, C₁₋₆ alcoxi, hidroxi-C₁₋₆ alquilo, C₁₋₆ alcoxi-C₁₋₆ alquilo, C₁₋₆ alcoxi-(C=O)-, CN, C₁₋₆ alquil-(C=O)-, R⁵R⁶N-, R⁵R⁶N-(C=O)-, R⁶(C=O)-R⁵N-, heterociclilo, heterociclil-N-, o fenil-N-, donde dicho heterociclilo o fenilo está opcionalmente sustituido con 1, 2, 3, ó 4 sustituyente/s donde cada uno es en forma independiente C₁₋₆ alquilo, C₁₋₆ alcoxi, oxo, o fenil-C₁₋₆ alcoxi; R² es C₁₋₆ alquilo, C₁₋₆ alcoxi, o C₁₋₆ alcoxi-C₁₋₆ alquilo; R³ es C₁₋₆ alquilo, C₁₋₆ alcoxi, o C₁₋₆ alcoxi-C₁₋₆ alquilo; R⁴ es C₁₋₆ alquilo; R⁵ es H, o C₁₋₆ alquilo; y R⁶ es H, o C₁₋₆ alquilo; o R¹ y R² forman, junto con los átomos del anillo a los cuales están unidos, un anillo heterocíclico insaturado de 6 miembros condensado, que contiene 1 ó 2 heteroátomo(s) que son N; o una sal aceptable farmacéuticamente o éster de los mismos; con la condición de que A no es 1,2,3-oxadiazol-3-ium-3-ilo.
ARP160101636A 2015-06-05 2016-06-02 DERIVADOS DE 2-(1-HETEROARILPIPERAZIN-4-IL)METIL-1,4-BENZODIOXANO COMO ANTAGONISTAS DE a2C AR104882A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20150169 2015-06-05

Publications (1)

Publication Number Publication Date
AR104882A1 true AR104882A1 (es) 2017-08-23

Family

ID=56132965

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101636A AR104882A1 (es) 2015-06-05 2016-06-02 DERIVADOS DE 2-(1-HETEROARILPIPERAZIN-4-IL)METIL-1,4-BENZODIOXANO COMO ANTAGONISTAS DE a2C

Country Status (15)

Country Link
US (1) US10774074B2 (es)
EP (1) EP3303327B1 (es)
JP (1) JP6806711B2 (es)
KR (1) KR102653543B1 (es)
CN (1) CN107709316B (es)
AR (1) AR104882A1 (es)
AU (1) AU2016272220B2 (es)
CA (1) CA2985400C (es)
EA (1) EA033085B1 (es)
ES (1) ES2794584T3 (es)
IL (1) IL255352B (es)
MX (1) MX2017015572A (es)
TW (1) TWI704145B (es)
WO (1) WO2016193551A1 (es)
ZA (1) ZA201707466B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019519582A (ja) * 2016-06-29 2019-07-11 オリオン コーポレーション ベンゾジオキサン誘導体およびその医薬用途
KR20240132345A (ko) 2022-01-07 2024-09-03 바이엘 악티엔게젤샤프트 수면 무호흡의 치료를 위한 2,3-디히드로벤조[b][1,4]디옥신-2-일메틸)피페라진-1-일 유도체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788052A (fr) * 1971-08-26 1973-02-26 Science Union & Cie Societe Fr Nouveaux derives de la sydnone imine
US4590196A (en) * 1984-08-23 1986-05-20 Bristol-Myers Company Analgesic 1,2-benzisothiazol-3-ylpiperazine derivatives
GB2167408B (en) 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
TWI242011B (en) * 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
FR2810979B1 (fr) * 2000-06-29 2002-08-23 Adir Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20040259883A1 (en) 2001-09-14 2004-12-23 Hiroshi Sakashita Thiazolidine derivative and medicinal use thereof
ATE374773T1 (de) 2002-04-03 2007-10-15 Orion Corp Polycyclische verbindungen als potenten alpha2- adrenoceptor antagonisten
ES2400339T3 (es) 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
US8013156B2 (en) 2003-03-19 2011-09-06 Exelixis, Inc. Tie-2 modulators and methods of use
TWI457122B (zh) * 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3-二氫苯並[1,4]戴奧辛-2-基甲基衍生物
TW201024282A (en) * 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds

Also Published As

Publication number Publication date
TW201708208A (zh) 2017-03-01
CN107709316A (zh) 2018-02-16
US20180215739A1 (en) 2018-08-02
NZ737533A (en) 2024-03-22
IL255352B (en) 2021-03-25
EA201792670A1 (ru) 2018-04-30
MX2017015572A (es) 2018-04-30
EP3303327A1 (en) 2018-04-11
TWI704145B (zh) 2020-09-11
JP6806711B2 (ja) 2021-01-06
CN107709316B (zh) 2021-08-17
KR102653543B1 (ko) 2024-04-03
EA033085B1 (ru) 2019-08-30
CA2985400A1 (en) 2016-12-08
KR20180011316A (ko) 2018-01-31
ZA201707466B (en) 2018-11-28
WO2016193551A1 (en) 2016-12-08
US10774074B2 (en) 2020-09-15
AU2016272220A1 (en) 2017-11-16
JP2018520123A (ja) 2018-07-26
ES2794584T3 (es) 2020-11-18
CA2985400C (en) 2023-08-29
IL255352A0 (en) 2017-12-31
EP3303327B1 (en) 2020-03-11
US20190292170A9 (en) 2019-09-26
AU2016272220B2 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
AR102177A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR103064A1 (es) Compuestos moduladores de fxr (nr1h4)
ECSP16076566A (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su aplicación a inhibidores de irak4
AR104884A1 (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
AR092270A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
CY1120325T1 (el) Τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις φωσφοϊνοσιτιδιου 3-κινασης
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR099785A1 (es) Compuestos heteroarilos y su uso como medicamentos
AR094300A1 (es) Derivados de quinolonas
AR097079A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGONISTA DE RECEPTORES MUSCARÍNICOS ASÍ COMO ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
AR106865A1 (es) Piridinas sustituidas y métodos de uso
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
AR090557A1 (es) DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR094496A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
AR092288A1 (es) Ligandos del receptor ep1
AR100440A1 (es) Derivados de carboxamida como inhibidores selectivos de smurf1
AR092749A1 (es) Compuestos farmaceuticos
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR109108A1 (es) Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2
AR111252A1 (es) Compuestos de isoxazol carboxamida y usos de los mismos

Legal Events

Date Code Title Description
FG Grant, registration